Invented by Caly Chien, Maura Erba, Meike Van Uffel, Alex Yu, Anasuya Hazra, Aragon Pharmaceuticals Inc

Prostate cancer is one of the most common types of cancer that affects men. It is estimated that around 1 in 9 men will be diagnosed with prostate cancer during their lifetime. The good news is that there are several treatment options available for prostate cancer, including anti-androgens.

Anti-androgens are a type of hormone therapy that is used to treat prostate cancer. They work by blocking the effects of male hormones, such as testosterone, on the prostate gland. This can help to slow down or stop the growth of cancer cells in the prostate gland.

The market for anti-androgens as a treatment for prostate cancer is growing rapidly. According to a report by Grand View Research, the global anti-androgen market is expected to reach $4.4 billion by 2025. This growth is driven by several factors, including an increase in the number of prostate cancer cases, an aging population, and advancements in medical technology.

One of the main advantages of anti-androgens is that they have fewer side effects than other types of prostate cancer treatments, such as chemotherapy. This makes them a popular choice for patients who want to maintain their quality of life while undergoing treatment.

There are several types of anti-androgens available on the market, including bicalutamide, flutamide, and enzalutamide. Each of these drugs works in a slightly different way, and the choice of drug will depend on the individual patient’s needs and medical history.

Despite the growing market for anti-androgens, there are still some challenges that need to be addressed. One of the main challenges is the development of resistance to anti-androgens. This can happen when cancer cells mutate and become resistant to the effects of the drugs. Researchers are currently working on developing new drugs and treatment strategies to overcome this challenge.

In conclusion, the market for anti-androgens as a treatment for prostate cancer is growing rapidly. These drugs offer a safe and effective treatment option for patients with prostate cancer, and are becoming increasingly popular due to their low side effects. While there are still some challenges that need to be addressed, the future looks bright for the anti-androgen market.

The Aragon Pharmaceuticals Inc invention works as follows

The present invention discloses pharmaceutical compositions and methods for treating prostate cancer. This includes castrate-resistant prostate cancer, as well as metastatic castration-resistant prostate cancer and nonmetastatic castration-resistant prostate cancer. A drug product approved by the FDA contains an anti-androgen chosen from enzalutamide apalutamide or darolutamide.

Background for Anti-androgens as a treatment for prostrate cancer

Prostate Cancer Stages


4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide (enzalutamide)

Certain Terminology

Routes for Administration and Pharmaceutical Compositions”.

Methods for Dosing Regimes and Treatment Regimens”.

Example 1

Phase 1 Clinical Trial Protocol: A randomized, open-label, two-way, crossover study to evaluate the relative bioavailability Apalutamide administered orally as whole tablets and as a mixture in applesauce in healthy subjects


Objectives and hypotheses

Overview of Study Design

Subject Selection

Study Drugs, Formulation, Dose, And Mode Of Administration

Study Evaluations

Statistical Methods

Detailed Clinical Trial Plan


Background: Absorption Distribution Metabolism and Excretion (ADME).

Safety in Healthy Subjects

Overall Rationale of the Study

Objectives and hypothese:

Click here to view the patent on Google Patents.